# High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

> **NCT06492759** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 29 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Medical Chart Review

## Key facts

- **NCT ID:** NCT06492759
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2027-02-12
- **Final completion:** 2028-02-13
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492759, "High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06492759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*